BioMarin Pharmaceutical Japan K.K.

Product Information : Drug for neuronal ceroid lipofuscinosis type 2

We provide information
about BioMarin’s products for healthcare professionals.

Home>To all healthcare professionals>Drug for neuronal ceroid lipofuscinosis type 2: Product Information

Product Information

Drug for neuronal ceroid lipofuscinosis type 2

BRINEURA® Intraventricular Injection 150mg

BRINEURA® Intraventricular Injection 150mg

BRINEURA®(Celluliponase alfa)
is an enzyme replacement therapy for the treatment of neuronal ceroid lipofuscinosis type 2.

BRINEURA® Intraventricular Injection 150mg
Generic Name Cerliponase alfa (genetically modified)
Indication Neuronal ceroid lipofuscinosis type 2
Dosage and Administration Usually, administer 300 mg of cerliponase alfa (genetically modified) by intraventricular infusion once every two weeks.
Reduce as appropriate for patient’s condition and/or age.

Materials on Our Products

For more information on diseases and products, please refer to the following PDF documents.

Package Insert Interview Form Explanation of
“Precautions for Use” Proper Use Guidelines Summary of
Product Information Materials
for patient explanation

Medical Reference

BioMarin Pharmaceutical Japan K.K. has established a medical information site " Medical Plus " For healthcare professionals .

Medical Plus
page top